Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Lisata Therapeutics ( (LSTA) ) is now available.
On October 8, 2025, Lisata Therapeutics entered into a non-exclusive license agreement with Catalent, Inc., allowing Catalent to use Lisata’s iRGD cyclic peptide, certepetide, in its SMARTag® ADC platform. This agreement positions Lisata to receive up to $10.5 million in milestone payments and tiered revenue sharing from future sales, enhancing its financial prospects and industry positioning.
The most recent analyst rating on (LSTA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Lisata Therapeutics stock, see the LSTA Stock Forecast page.
Spark’s Take on LSTA Stock
According to Spark, TipRanks’ AI Analyst, LSTA is a Neutral.
Lisata Therapeutics is navigating through financial difficulties with persistent losses and negative cash flows. The stock’s technical indicators and valuation reflect a challenging financial position. However, recent advancements in clinical trials and regulatory achievements offer potential upside, albeit with high risk.
To see Spark’s full report on LSTA stock, click here.
More about Lisata Therapeutics
Lisata Therapeutics, Inc. operates in the biotechnology industry, focusing on developing novel therapeutic products. The company is known for its innovative approaches in drug development, particularly in the use of cyclic peptides as drug conjugates.
Average Trading Volume: 36,553
Technical Sentiment Signal: Strong Sell
Current Market Cap: $21.98M
See more insights into LSTA stock on TipRanks’ Stock Analysis page.